- Home
- GCI vs ORKA Comparison
GCI vs ORKA Comparison
Compare GCI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- ORKA
- Stock Information
- Founded
- GCI 1997
- ORKA 2004
- Country
- GCI United States
- ORKA United States
- Employees
- GCI N/A
- ORKA N/A
- Industry
- GCI Newspapers/Magazines
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GCI Consumer Discretionary
- ORKA Health Care
- Exchange
- GCI Nasdaq
- ORKA Nasdaq
- Market Cap
- GCI 509.6M
- ORKA 354.2M
- IPO Year
- GCI N/A
- ORKA N/A
- Fundamental
- Price
- GCI $3.63
- ORKA $11.31
- Analyst Decision
- GCI Buy
- ORKA Strong Buy
- Analyst Count
- GCI 3
- ORKA 8
- Target Price
- GCI $5.70
- ORKA $39.71
- AVG Volume (30 Days)
- GCI 1.7M
- ORKA 328.9K
- Earning Date
- GCI 07-31-2025
- ORKA 08-15-2025
- Dividend Yield
- GCI N/A
- ORKA N/A
- EPS Growth
- GCI N/A
- ORKA N/A
- EPS
- GCI 0.36
- ORKA N/A
- Revenue
- GCI $2,445,127,000.00
- ORKA N/A
- Revenue This Year
- GCI N/A
- ORKA N/A
- Revenue Next Year
- GCI N/A
- ORKA N/A
- P/E Ratio
- GCI $10.03
- ORKA N/A
- Revenue Growth
- GCI N/A
- ORKA N/A
- 52 Week Low
- GCI $2.55
- ORKA $5.49
- 52 Week High
- GCI $5.93
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- GCI 54.09
- ORKA N/A
- Support Level
- GCI $3.15
- ORKA N/A
- Resistance Level
- GCI $3.50
- ORKA N/A
- Average True Range (ATR)
- GCI 0.13
- ORKA 0.00
- MACD
- GCI -0.01
- ORKA 0.00
- Stochastic Oscillator
- GCI 64.04
- ORKA 0.00
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.